1/12
11:40 am
qncx
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential [Seeking Alpha]
High
Report
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential [Seeking Alpha]
1/6
08:02 am
qncx
Quince Therapeutics (NASDAQ:QNCX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
12/30
04:14 pm
qncx
Quince Therapeutics (NASDAQ:QNCX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/15
02:45 pm
qncx
Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its price target raised by analysts at D. Boral Capital from $4.00 to $5.00. They now have a "buy" rating on the stock.
12/15
08:00 am
qncx
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Medium
Report
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
12/10
04:56 pm
qncx
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders [Yahoo! Finance]
High
Report
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders [Yahoo! Finance]
12/10
04:05 pm
qncx
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
High
Report
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
11/24
08:00 am
qncx
Quince Therapeutics to Participate at Investor Events in December 2025
High
Report
Quince Therapeutics to Participate at Investor Events in December 2025
11/13
09:01 am
qncx
Quince Therapeutics (NASDAQ:QNCX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $4.00 price target on the stock.
Low
Report
Quince Therapeutics (NASDAQ:QNCX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $4.00 price target on the stock.
11/12
04:05 pm
qncx
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Low
Report
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
11/10
04:05 pm
qncx
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
Low
Report
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia